Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2013, Article ID 434618, 5 pages
http://dx.doi.org/10.1155/2013/434618
Clinical Study

The Influence of Long Term Hydrochlorothiazide Administration on the Relationship between Renin-Angiotensin-Aldosterone System Activity and Plasma Glucose in Patients with Hypertension

1Department of Emergency Medicine, The Sichuan Provincial People’s Hospital, Chengdu 610072, China
2Department of Ophthalmology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA

Received 6 August 2013; Accepted 4 October 2013

Academic Editor: Yan Chen

Copyright © 2013 Xu Xiao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Matayoshi, K. Kamide, S. Takiuchi et al., “Relationship between insulin resistance and the renin-angiotensin system: analysis for patients with essential and renovascular hypertension,” Clinical and Experimental Hypertension, vol. 29, no. 7, pp. 479–487, 2007. View at Publisher · View at Google Scholar
  2. A. J. Scheen, “Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system,” Drugs, vol. 64, no. 22, pp. 2537–2565, 2004. View at Publisher · View at Google Scholar
  3. X. D. Li, T. T. Fang, and J. Z. Lv, “Analysis of antihypertensive drug use in our hospital from June 2004 to December 2006,” China Pharmacy, vol. 19, no. 32, p. 2497, 2008 (Chinese). View at Google Scholar
  4. P. X. Shaw, L. Zhang, M. Zhang et al., “Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 34, pp. 13757–13762, 2012. View at Publisher · View at Google Scholar
  5. X. Jiang, H. Sheng, J. Li et al., “Association between renin-angiotensin system gene polymorphism and essential hypertension: a community-based study,” Journal of Human Hypertension, vol. 23, no. 3, pp. 176–181, 2009. View at Publisher · View at Google Scholar
  6. A. J. Scheen, “Renin-angiotensin system inhibition prevents type 2 diabetes mellitus—part 2: overview of physiological and biochemical mechanisms,” Diabetes & Metabolism, vol. 30, no. 6, p. 498, 2004. View at Google Scholar
  7. J. M. Richey, M. Ader, D. Moore, and R. N. Bergman, “Angiotensin II induces insulin resistance independent of changes in interstitial insulin,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 277, no. 5, part 1, pp. E920–E926, 1999. View at Google Scholar
  8. M. Chandran, S. A. Phillips, T. Ciaraldi, and R. R. Henry, “Adiponectin: more than just another fat cell hormone?” Diabetes Care, vol. 26, no. 8, pp. 2442–2450, 2003. View at Publisher · View at Google Scholar
  9. American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases, “The prevention or delay of type 2 diabetes,” Diabetes Care, vol. 25, no. 4, pp. 742–749, 2002. View at Google Scholar
  10. H. X. Qian, X. S. Li, S. L. Tang et al., “Progress in research of the influence of Rosiglitazone on type II diabetic nephropathy,” China Pharmacy, vol. 20, no. 32, p. 621, 2009 (Chinese). View at Google Scholar